Insulet Total Liab vs Other Stockholder Equity Analysis
PODD Stock | USD 262.00 4.58 1.72% |
Insulet financial indicator trend analysis is infinitely more than just investigating Insulet recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Insulet is a good investment. Please check the relationship between Insulet Total Liab and its Other Stockholder Equity accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Insulet. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Insulet Stock refer to our How to Trade Insulet Stock guide.
Total Liab vs Other Stockholder Equity
Total Liab vs Other Stockholder Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Insulet Total Liab account and Other Stockholder Equity. At this time, the significance of the direction appears to have strong relationship.
The correlation between Insulet's Total Liab and Other Stockholder Equity is 0.64. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Other Stockholder Equity in the same time period over historical financial statements of Insulet, assuming nothing else is changed. The correlation between historical values of Insulet's Total Liab and Other Stockholder Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Insulet are associated (or correlated) with its Other Stockholder Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Stockholder Equity has no effect on the direction of Total Liab i.e., Insulet's Total Liab and Other Stockholder Equity go up and down completely randomly.
Correlation Coefficient | 0.64 |
Relationship Direction | Positive |
Relationship Strength | Significant |
Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Other Stockholder Equity
Most indicators from Insulet's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Insulet current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Insulet. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Insulet Stock refer to our How to Trade Insulet Stock guide.At present, Insulet's Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value is expected to grow to about 10.3 B, whereas Sales General And Administrative To Revenue is forecasted to decline to 0.17.
2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 500K | 9.8M | 28.9M | 30.3M | Tax Provision | 3.7M | 5.2M | 9.1M | 9.6M |
Insulet fundamental ratios Correlations
Click cells to compare fundamentals
Insulet Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Insulet fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 1.1B | 1.9B | 2.0B | 2.3B | 2.6B | 2.7B | |
Total Stockholder Equity | 75.9M | 603.6M | 556.3M | 476.4M | 732.7M | 769.3M | |
Net Debt | 511.8M | 96.1M | 457.2M | 727.1M | 711.6M | 747.2M | |
Cash | 376.1M | 947.6M | 791.6M | 674.7M | 704.2M | 739.4M | |
Other Assets | 25M | 79M | 106.1M | 147.1M | 1.0 | 0.95 | |
Cash And Short Term Investments | 376.1M | 947.6M | 791.6M | 674.7M | 704.2M | 739.4M | |
Common Stock Shares Outstanding | 62.3M | 65.9M | 68.6M | 69.9M | 73.6M | 44.7M | |
Liabilities And Stockholders Equity | 1.1B | 1.9B | 2.0B | 2.3B | 2.6B | 2.7B | |
Other Stockholder Equity | 749M | 1.3B | 1.2B | 1.0B | 1.1B | 620.4M | |
Total Liab | 1.1B | 1.3B | 1.5B | 1.8B | 1.9B | 1.9B | |
Total Current Assets | 591M | 1.2B | 1.3B | 1.3B | 1.6B | 1.7B | |
Short Long Term Debt Total | 891.5M | 1.1B | 1.3B | 1.4B | 1.4B | 1.5B | |
Other Current Liab | 96.4M | 132.7M | 162.5M | 306.4M | 379.1M | 398.1M | |
Total Current Liabilities | 157.7M | 207.8M | 228.8M | 364.7M | 451.2M | 473.8M | |
Property Plant And Equipment Net | 399.4M | 478.7M | 536.5M | 599.9M | 692.8M | 727.4M | |
Current Deferred Revenue | 3.2M | 5.4M | 3.5M | 16.1M | 15.4M | 16.2M | |
Retained Earnings | (672M) | (666.3M) | (649.5M) | (584.3M) | (378M) | (396.9M) | |
Accounts Payable | 54.5M | 54.1M | 37.7M | 30.8M | 19.2M | 19.7M | |
Non Current Assets Total | 551.9M | 624.2M | 719M | 937.1M | 1.0B | 1.1B | |
Non Currrent Assets Other | 41.1M | 77M | 106.1M | 210M | 135.5M | 142.3M | |
Non Current Liabilities Total | 909.3M | 1.1B | 1.3B | 1.4B | 1.4B | 1.5B | |
Other Current Assets | 31.1M | 63M | 74M | 86.9M | 116.4M | 122.2M | |
Property Plant And Equipment Gross | 399.4M | 478.7M | 715.7M | 834.6M | 958.1M | 1.0B | |
Accumulated Other Comprehensive Income | (1.2M) | 5.5M | (2.2M) | 20M | 8M | 8.4M | |
Other Liab | 7M | 17.8M | 14.9M | 8.3M | 9.5M | 5.4M | |
Long Term Debt | 887.9M | 1.0B | 1.2B | 1.4B | 1.4B | 1.4B | |
Net Receivables | 82.8M | 83.8M | 161M | 205.6M | 359.7M | 377.7M | |
Short Term Investments | 175.0M | 162.4M | 40.4M | 50.8M | 26.9M | 25.6M | |
Inventory | 101M | 154.3M | 303.2M | 346.8M | 402.6M | 422.7M | |
Property Plant Equipment | 399.4M | 478.7M | 536.5M | 599.9M | 689.9M | 724.4M | |
Net Tangible Assets | 22.9M | 535.1M | 479.9M | 349.2M | 401.6M | 421.7M | |
Good Will | 39.8M | 39.6M | 39.8M | 51.7M | 59.5M | 44.1M | |
Retained Earnings Total Equity | (672M) | (666.3M) | (649.5M) | (584.3M) | (525.9M) | (552.2M) | |
Long Term Debt Total | 887.9M | 1.0B | 1.2B | 1.4B | 1.6B | 1.7B | |
Capital Surpluse | 749M | 1.3B | 1.2B | 1.0B | 1.2B | 899.1M | |
Deferred Long Term Liab | 19.9M | 21.9M | 26.1M | 31.3M | 36.0M | 37.8M | |
Non Current Liabilities Other | 21.4M | 17.8M | 14.9M | 35.7M | 37.9M | 39.8M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Insulet is a strong investment it is important to analyze Insulet's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Insulet's future performance. For an informed investment choice regarding Insulet Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Insulet. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. For information on how to trade Insulet Stock refer to our How to Trade Insulet Stock guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Insulet. If investors know Insulet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Insulet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.46 | Earnings Share 5.86 | Revenue Per Share 28.341 | Quarterly Revenue Growth 0.257 | Return On Assets 0.0757 |
The market value of Insulet is measured differently than its book value, which is the value of Insulet that is recorded on the company's balance sheet. Investors also form their own opinion of Insulet's value that differs from its market value or its book value, called intrinsic value, which is Insulet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Insulet's market value can be influenced by many factors that don't directly affect Insulet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Insulet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Insulet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Insulet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.